AUTHORS
Sharlene Dong, MD, MS, Malvika Gupta, MD2, Rahul Banerjee, MD3, Sarvari V. Yellapragada, MD4, Lorenzo Gensini, MD5, David Berrios, M.D.6, Maudood Ahmed Rana7, Doris K. Hansen, MD8, Omar Alexis Castaneda Puglianini, MD9, Ariel F. Grajales-Cruz, MD10, Rachid Baz, MD11, Frederick L. Locke, MD12, Lauren C Peres, PhD, MPH13, Danai Dima, MD14, Surbhi Sidana, MD15, Lekha Mikkilineni, MD, MA16, Christopher Ferreri, MD17, Cindy Varga, MD18, Shebli Atrash, MD19, Peter M Voorhees, MD20, Doug W. Sborov, MD, MS21, Christopher Cahoon, PharmD22, Binoy Yohannan, MD23, Veronika Bachanova, MD, PhD24, Megan M Herr, PhD25, Francesca Cottini, MD26, Ashley Rosko, MD27, Noa Biran, MD28, Harsh Parmar, MD29, Joseph Franz, MD30, Lindsay Fogel, MD31, Kimberly Burcher, M.D.32, Sneha Purvey, MD33, Marcus Geer, MD34, Ran Reshef, MD35, James A Davis, PharmD, BCOP36, Asya Varshavsky, MD37, Jennifer Ann Kanakry, MD38, Timothy O'Brien, MD39, Lawrence Liu, MD40, Shonali Midha, MD41, Omar Nadeem, MD42, Karen Sweiss, PharmD43, Matias Eugenio Sanchez, MD44, Andre De Menezes Silva Corraes, MD45, Shaji Kumar, MD46, Aimaz Afrough, MD47, Larry D Anderson Jr, MD, PhD48, Hira Mian, MD49, Susan Bal, MD50, Nisha Joseph, MD51, Krina Patel Jr, MD, MSc52, Yi Lin Jr, MD, PhD53, Oren Pasvolsky, MD54, Andrew J. Portuguese, MD55
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Fred Hutchinson Cancer Center, Seattle, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
14 Fred Hutchinson Cancer Center, Seattle, United States
15 Stanford University School of Medicine, Stanford, California, United States
16 Stanford University School of Medicine, Stanford, California, United States
17 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
18 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
19 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
20 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
21 Huntsman Cancer Institute, Salt Lake City, Utah, United States
22 Huntsman Cancer Institute, Salt Lake City, Utah, United States
23 University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
24 University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
25 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
26 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
27 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
28 Hackensack University Medical Center John Theurer Cancer Center, Nutley, New Jersey, United States
29 Hackensack University Medical Center John Theurer Cancer Center, Nutley, New Jersey, United States
30 Hackensack University Medical Center John Theurer Cancer Center, Nutley, New Jersey, United States
31 Columbia University Irving Medical Center, New York, New York, United States
32 Duke Cancer Institute, Durham, North Carolina, United States
33 Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, United States
34 University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
35 Columbia University Irving Medical Center, New York, New York, United States
36 Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
37 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
38 MedStar Georgetown University Hospital, Washington, District of Columbia, United States
39 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
40 Cedars-Sinai Medical Center, Los Angeles, California, United States
41 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
42 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
43 University of Illinois Cancer Center, Chicago, United States
44 University of Illinois Cancer Center, Chicago, United States
45 Mayo Clinic, Rochester, Minnesota, United States
46 Mayo Clinic, Rochester, Minnesota, United States
47 UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States
48 UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States
49 McMaster University, Hamilton, Ontario, Canada
50 University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
51 Emory University Winship Cancer Institute, Atlanta, Georgia, United States
52 The University of Texas MD Anderson Cancer Center, Houston, United States
53 Mayo Clinic, Rochester, Minnesota, United States
54 The University of Texas MD Anderson Cancer Center, Houston, United States
55 Fred Hutchinson Cancer Center, Seattle, United States
ABSTRACT
Introduction: Circadian rhythms regulate immune-cell trafficking and T-cell activation. Prior studies of chimeric antigen receptor (CAR) T-cell therapy in lymphoma have reported conflicting associations between infusion timing and outcomes (Luan Blood 2026; Dowling Blood 2026). We evaluated whether CAR T-cell infusion time was associated with response, survival, and toxicities in a multicenter real-world RRMM cohort.
Methods: We retrospectively studied RRMM patients (pts) who received commercial ciltacabtagene autoleucel at 19 U.S. Myeloma Immunotherapy Consortium centers. Local infusion clock time was modeled as a continuous variable per 1-hr and categorized based on median infusion time (early ≤ median vs late > median). Site-relative time was calculated as hours from each site’s median and standardized as a within-site z-score. Centers with <20 evaluable pts were excluded from site-relative analyses. Endpoints included 30-day overall response rate (ORR), progression-free survival (PFS), overall survival (OS), non-relapse mortality (NRM), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Responses/toxicities followed IMWG/ASTCT criteria. Binary endpoints used logistic regression, PFS/OS used site-stratified Cox models, and NRM used Fine-Gray regression. Additional site-adjusted logistic models were evaluated as sensitivity analyses. Multivariable (MV) models adjusted for age, ECOG ≥2, ≥4 prior lines of therapy (LOT), ≥1 high-risk cytogenetic abnormality (HRCA), extramedullary disease (EMD), prior BCMA therapy, and within-site timing z-score. Multicollinearity was low between the late-vs-early infusion variable and within-site timing z-score. Sensitivity analyses used stabilized average-treatment-effect inverse-probability-of-treatment weighting (ATE-IPTW) with the same covariates. For each exposure, Benjamini-Hochberg FDR adjustment was applied across the nine endpoints reported.
Results: Among 1306 pts, the median age was 66 years (yrs) (IQR 59-71), 40% (n=520) had ≥1 HRCA, 17% (n=225) had EMD, and 61% (n=798) received ≥4 prior LOT. Median local infusion time was 11:36 (IQR 10:48–12:34), and site medians ranged from 10:30 to 14:04. Baseline characteristics between early vs late infusion groups were similar by age (p=0.8), sex (p=0.8), ECOG (p=0.7), ≥ 1 HRCA (p=0.8), and EMD (p=0.13). Pts who received late infusion were more likely to have received ≥4 prior LOT (p=0.039) and had a higher median ferritin (193 vs 146 ng/mL, p=0.032). In evaluable pts, 30-day ORR was 86.2% (995/1154) and best ORR was 96.2% (1203/1250). Early vs late infusion showed no differences in 30-day ORR (85.1% vs 87.4%) or best ORR (97.2% vs 95.3%) by local clock time or site-relative time. Unadjusted analyses suggested shorter PFS with late infusion by local time (p=0.010) and site-relative time (p=0.00025) and shorter OS by site-relative time (p=0.0016) but associations attenuated after MV adjustment. Late vs early infusion was not associated with PFS (adjusted HR 0.97, 95% CI, 0.70–1.34, p=0.844, q=0.844) or OS (adjusted HR 0.95, 95% CI, 0.62–1.45, p=0.806, q=0.844), with concordant IPTW estimates (PFS HR 1.09, p=0.470; OS HR 1.01, p=0.930). Continuous local clock time was also not associated with PFS or OS. In the Fine-Gray model, late vs early infusion was not associated with NRM (sHR 0.83, 95% CI, 0.54-1.29, p=0.413, q=0.531, n=1214, 103 events). Any-grade CRS occurred in 74.0–77.2% and did not differ by timing. Any-grade ICANS occurred more frequently after late infusion based on local clock time (20.1% vs 12.3%, p<0.001) and site-relative time (19.3% vs 13.5%, p=0.0055). The association persisted in MV (adjusted OR 1.68, 95% CI, 1.18–2.40, p=0.004, q=0.035) and IPTW analyses (OR 1.90, 95% CI, 1.31–2.76, p<0.001). Grade ≥3 ICANS was not associated with late infusion (adjusted OR 1.55, 95% CI, 0.66-3.59, p=0.312, q=0.512). No other core toxicity endpoint was significant after FDR adjustment.
Conclusions: Infusion schedules varied substantially across centers. Local or site-relative infusion time was not independently associated with response, PFS, OS, NRM, CRS or severe ICANS in RRMM. While unadjusted analyses suggested shorter PFS with later infusions, this association was not seen on MV analysis and likely reflects underlying confounding. However, later infusion was associated with higher odds of any-grade ICANS across adjusted analyses. Further analyses will be presented at the meeting.
DISCLOSURES
Sharlene Dong, MD, MS: No relevant conflicts of interest to declare.